Teva Pharmaceutical Industries Ltd. announced that the US Food and Drug Administration has granted final approval for the company's Abbreviated New Drug Application (ANDA) to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid (lansoprazole) delayed-release capsules, 15 mg and 30 mg.

Annual sales of Prevacid delayed-release capsules were approximately US$ 2.97 billion in the United States for the twelve months that ended June 30, 2009 based on IMS sales data.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is the world's leading generic pharmaceutical company and is among the top 20 pharmaceutical companies in the world.